Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Jaya Julie Joshi, Heather Coffey, Erik Corcoran, et al.
Cancer Research (2017) Vol. 77, Iss. 24, pp. 6999-7013
Open Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet, Robert Montal, Daniela Sia, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 10, pp. 599-616
Open Access | Times Cited: 1621
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Agustı́n Albillos, Andrea De Gottardi, María Rescigno
Journal of Hepatology (2019) Vol. 72, Iss. 3, pp. 558-577
Open Access | Times Cited: 1390
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
Yaojie Fu, Shanshan Liu, Shan Zeng, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 337
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 299
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai, Zhan Zhou, Zhuchu Chen, et al.
Cells (2019) Vol. 8, Iss. 6, pp. 614-614
Open Access | Times Cited: 240
Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response
Stefano Caruso, Anna-Line Calatayud, Jill Pilet, et al.
Gastroenterology (2019) Vol. 157, Iss. 3, pp. 760-776
Open Access | Times Cited: 156
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
Xiangyuan Luo, Kongming Wu, Xingxing He
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 152
New developments in the biology of fibroblast growth factors
David M. Ornitz, Nobuyuki Itoh
WIREs Mechanisms of Disease (2022) Vol. 14, Iss. 4
Open Access | Times Cited: 96
Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases
Xiaokun Li, Weiqin Lu, Alexei Kharitonenkov, et al.
Journal of Internal Medicine (2024) Vol. 295, Iss. 3, pp. 292-312
Open Access | Times Cited: 24
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 4
FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
Aroosha Raja, Inkeun Park, Farhan Haq, et al.
Cells (2019) Vol. 8, Iss. 6, pp. 536-536
Open Access | Times Cited: 130
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Bin Chen, Lana X. Garmire, Diego F. Calvisi, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 4, pp. 238-251
Open Access | Times Cited: 118
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
Robert Roskoski
Pharmacological Research (2019) Vol. 151, pp. 104567-104567
Closed Access | Times Cited: 114
Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives
Emmanuel Somm, François R. Jornayvaz
Endocrine Reviews (2018) Vol. 39, Iss. 6, pp. 960-989
Open Access | Times Cited: 94
Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
Brendan Farrell, Alexander L. Breeze
Biochemical Society Transactions (2018) Vol. 46, Iss. 6, pp. 1753-1770
Open Access | Times Cited: 92
Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors
Xiaoyun Lu, Jeff B. Smaill, Adam V. Patterson, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 1, pp. 58-83
Closed Access | Times Cited: 89
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4
Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12542-12573
Closed Access | Times Cited: 86
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss, Flavia Adler, Alexandra Buhles, et al.
Molecular Cancer Therapeutics (2019) Vol. 18, Iss. 12, pp. 2194-2206
Open Access | Times Cited: 85
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies
Liwei Lang, Yong Teng
Cells (2019) Vol. 8, Iss. 1, pp. 31-31
Open Access | Times Cited: 80
tRNA-derived fragments (tRFs): establishing their turf in post-transcriptional gene regulation
Srikar Krishna, S. Raghavan, Ramanuj DasGupta, et al.
Cellular and Molecular Life Sciences (2021) Vol. 78, Iss. 6, pp. 2607-2619
Closed Access | Times Cited: 71
Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review
Jia Zheng, Wei Zhang, Linfeng Li, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 50
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 43
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Y. Qin, Shisong Han, Yahan Yu, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1808-1831
Closed Access | Times Cited: 11
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6549-6569
Closed Access | Times Cited: 8
Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
Xiaoyun Lu, Hao Chen, Adam V. Patterson, et al.
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 6, pp. 2905-2915
Closed Access | Times Cited: 72
Page 1 - Next Page

Scroll to top